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Opinion statement
Status epilepticus treatment involves the use of several pharmacologic compounds,
which are conceptually divided into three successive and additional lines of action.
Because of their rapid onset of action, benzodiazepines represent the first approach;
these are followed by classic antiepileptic drugs that are administered intravenously.
In refractory episodes, pharmacologic coma induction with an appropriate anesthetic
is advocated. Apart from first-line compounds, the level of evidence for medications
used in status epilepticus is extremely limited. It is important to specifically address
etiology in order to maximize the impact of the antiepileptic therapy. Fine-tuning of
the treatment strategy, mainly regarding the choice of whether to induce coma, should
be approached by balancing the benefits of rapid control of the status epilepticus with
the risks of adverse effects. Although each status epilepticus episode should be treated
as rapidly as possible, it appears advisable to reserve coma induction for those forms,
such as generalized convulsive status, that have been shown to present a consistent
risk of neurologic sequelae.
Introduction
Status epilepticus (SE), the most common neurologic
emergency after stroke, requires multidisciplinary
management, including paramedics and nurses, neu-
rologists, emergency specialists, and intensive care unit
physicians; at times, pharmacologists and members
of other medical specialties (eg, infectious disease
specialists or immunologists) complete the team. SE
must be treated as soon as possible in order to prevent
potentially harmful complications such as functional
neurologic and neuropsychological impairment or
even death [1–3]. Despite the important impact of
SE, to date there is only a relatively low degree of
evidence concerning its pharmacologic treatment,
perhaps because of the marked variability of SE
forms and the challenges of designing large collab-
orative trials (including the difficulty of gathering
financial support). As a result, past therapy strate-
gies have been relatively heterogeneous. Although
in recent years several national and international
guidelines have been published, it remains unclear
whether these are thoroughly applied and whether
they have led to an improvement of SE prognosis.
Moreover, it seems important to adapt treatments
to the specific circumstances of each patient, in
order to maximize the ratio between efficacy and
adverse effects.
This paper reviews pharmacologic agents used in
SE treatment and gives some practical suggestions
about treatment options and strategies.
General treatment considerations
Seizures (and, if they are prolonged, SE) result from
an imbalance between inhibitory neuronal inputs
(mostly through GABAA receptors) and excitatory
inputs (predominantly glutamate-mediated, via kai-
nate and AMPA receptors) [1,4]. This characteristic
may be viewed as a rationale for beginning SE treat-
ment with benzodiazepines, which are rapidly acting
GABAergic agents. However, in ongoing SE, GABA
resistance develops progressively, following receptor
internalization into the cell and subunit changes;
this process leads to a shift toward self-sustaining
glutamate-mediated excitotoxicity, resulting primari-
ly from the activation of NMDA receptors. These
changes likely explain both refractoriness to benzo-
diazepines and excitotoxic neuronal damage.
SE treatment aims at stopping seizure activity and
concomitantly preventing complications. First, pulmo-
nary and cardiac functions need to be secured; in parallel,
a targeted examination and history-taking must be
performed to detect possible SE imitators, such as move-
ment disorders (eg, shivering in the ICU) or psychogenic
seizures, which may account for a not-negligible pro-
portion of “convulsions” in the emergency room [5].
Sequential laboratory and neuroradiologic workups
are needed to address SE etiology, which may greatly
influence the success of specific treatments, including
the choice of antiepileptic drugs (AEDs). As a rule of
thumb, SE treatment should be performed with the
help of electroencephalography (EEG). Prolonged
recordings are best, as they not only allow judgments
about the efficacy of administered agents but also
are required for the diagnosis of nonconvulsive SE (ie,
complex-partial SE, absence SE, or SE in coma).
Treatment
Pharmacologic treatment
& It is useful to categorize pharmacologic SE treatment into three steps
[2], bearing in mind that, in general, intravenous administration is to
be preferred because of the possibility of fast loading. The first
treatment line is represented exclusively by benzodiazepines aiming
at rapid SE control, the second line by classic AEDs targeting early
resistant forms of SE and long-term coverage following anticipated
control of SE, and the third line by general anesthetics used for
refractory SE. This approach should be not only sequential,
meaning that the next step is initiated as soon as the previous one
is considered to have failed, but also additional, implying that
previous treatment lines should not be discontinued, thus allowing
complementary actions thanks to different pharmacodynamic mecha-
nisms. A simple protocol with corresponding timing is proposed in
Fig. 1. Awareness of a protocol allows a smooth interplay between
different team members (paramedics, emergency or ICU team,
neurologists) and probably reduces wasted time during emergency
management. However, every protocol, even if simple, should be
interpreted according to the situation and modified as needed. Of
note, if a glucose solution is administered to the patient, it is
important to add thiamine to prevent a Wernicke encephalopathy.
& Although multiple pharmacologic options are used to treat SE, there
is a substantial lack of comparative, high-level, evidence-based infor-
mation. Use of a treatment protocol with the three steps is recom-
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mended in order to facilitate and accelerate the early practical
management. The patient’s background, including etiology and age,
largely determines the prognosis, so it is important to consider these
aspects and to adapt the treatment strategy to each particular case, in
order tominimize the risks of overtreatment or undertreatment. The art
of treating SE effectively residesmore in the fine-tuning of the approach
than in the automatic application of sequential agents. It is hoped that
future trials will draw attention to the best strategy for the management
of this heterogeneous condition.
First treatment line
& This is the only treatment step that has been studied in several
randomized controlled trials. The first, carried out more than
20 years ago on a relatively limited number of patients, disclosed
a nonsignificant trend toward better response to 4 mg lorazepam
as compared to 10 mg diazepam [6, Class I]. Similarly, a large
prehospital trial at the beginning of this decade, using relatively
low doses, found that 2 mg lorazepam had a nonsignificant superiority
over 5 mg diazepam, both treatments were significantly better than
placebo, and cardiovascular and respiratory complications were similar
among all three groups [7, Class I], suggesting that SE per se may be
responsible for causing hypotension and respiratory depression. A large
VA trial, focusing on generalized convulsive SE and assessing the effi-
cacy of 0.1 mg/kg lorazepam, 15 mg/kg phenobarbital, 0.15 mg/kg
diazepam followed by 18 mg/kg phenytoin, and 18 mg/kg phenytoin
Figure 1. Overview of pharmacologic
treatment of status epilepticus (SE). This
protocol is by no means highly evidence-
based, but only summarizes the author’s
opinion and experience. EEG—
electroencephalography.
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alone, disclosed better efficacy of lorazepam versus phenytoin alone,
but not in comparison to the other arms [8, Class I]. Of note, this was
the only trial adapting the dosage to body weight. The overall response
in overt SE (about 60%) was higher than in subtle SE (about 20%).
& SE becomes more refractory to treatment with time, and the first
treatment has a far better chance of success than the second or third,
regardless of the drug (55% vs 7% vs 2% in the VA trial) [9, Class I],
so it appears mandatory to administer intravenous drugs that act
quickly. In this view, benzodiazepines are the best alternative, over
phenobarbital and phenytoin. Compounds with a long elimination
half-life in the central nervous system (CNS) are preferred, tominimize
the risk of withdrawal or rebound seizures as drug levels decline.
& The administration of a benzodiazepine bolus during SE may induce
respiratory and circulatory collapse (about 10% to 26%) [7,8]; there-
fore,monitoring of these functions ismandatory during administration
of benzodiazepines.
& Note that tonic SE in patients with developmental delay, suffering
from epileptic encephalopathies, may rarely be aggravated by
benzodiazepines.
Lorazepam
Standard dosage Lorazepam is administered as a slow bolus of 0.1 mg/kg (2 mg/min) it enters
the brain in less than 2 to 3 minutes [10] and has a long duration of action
(at least 12 h), because it is less likely than diazepam to redistribute in the fat
tissue [11]; the protein binding is estimated at 90%. Its elimination half-life
is about 8 to 25 h [10,11]
Contraindications Hypersensitivity to the compound; absence of respiratory monitoring.
Main drug interactions None.
Main side effects Sedation, respiratory depression.
Clonazepam
Standard dosage Clonazepam is administered at a bolus of 0.025 mg/kg. It reaches the brain
within 1 minute [10], and, despite its lipophilia, has a stable action over
time. It has a plasma half-life of up to 38 h and moderate protein binding
(65%) [12]. It is relatively widely used in Europe, but it is not approved by
the US Food and Drug Administration as a treatment for SE.
Contraindications Hypersensitivity to the compound; absence of respiratory monitoring.
Main drug interactions None.
Main side effects Sedation, respiratory depression.
Midazolam
Standard dosage Midazolam usually is given at a dose of 0.1 to 0.2 mg/kg, but doses up to
0.5 mg/kg have been reported [13]. It has a short half-life (about 2 h) but
represents a valuable alternative when intravenous lines are not available
or in treating children, as intranasal or buccal administration is possible.
Protein binding is very high (97%).
Contraindications Hypersensitivity to the compound; absence of respiratory monitoring.
Status Epilepticus Rossetti 103
Main drug interactions None.
Main side effects Sedation, respiratory depression.
Diazepam
Standard dosage Diazepam is administered intravenously at 0.2 mg/kg (5 mg/min); it enters the
brain in less than 10 s, but its free fraction redistributes in fat tissue owing to its
high lipophilia. Therefore, after about 20minutes, drug levels in the brain decline
significantly [11]. It is tightly bound to proteins (99%). This agent also may be
administered rectally—a helpful alternative, especially for children.
Contraindications Hypersensitivity to the compound; absence of respiratory monitoring.
Main drug interactions None.
Main side effects Sedation, respiratory depression.
Second treatment line
& No large-scale, prospective comparative assessments among AEDs
used as second-line or third-line SE treatment have been performed
to date. The VA study included an arm using phenytoin (which acts
principally through sodium channel modulation) as initial SE treat-
ment and an arm using phenobarbital (mainly a GABAA agonist); it
found a nonsignificant trend toward better efficacy with phenobarbital
(58% vs 44% [8]).
& Intravenous valproate has been repeatedly reported to be efficacious
for several SE types [14,15], probably in view of its multimodal
pharmacodynamic action, including GABA, sodium channel, and
calcium channelmodulations. It lacks significant cardiovascular adverse
reactions, so there is no need of concurrent monitoring, a potential
advantage in out-of-hospital situations. Some studies comparing it with
phenytoin were recently published [14,16,17; Class III], but they are
relatively small and suffer from major methodologic pitfalls.
& Levetiracetam has also been employed in SE treatment for several
years [18]; the recent availability of an intravenous form renders it
even more promising [19•,20•; Class IV]. It has good tolerability, but
no comparative trial has been published to date.
& The recently marketed lacosamide was available in an intravenous
form from the beginning; it acts by modulating the slow inactivation
of the sodium channel and by interfering with the collapsin protein
function. Experience in SE is still anecdotal, however [21•, Class IV].
& After loading of one of these agents, serum levels should be checked
periodically to ensure therapeutic concentrations.
Phenytoin
Standard dosage Phenytoin is loaded at 20 mg/kg (maximal infusion rate, 50 mg/min).
Maximal concentrations in the CNS are reached after 20 minutes [11]. The
elimination half-life is about 24 h, but it becomes significantly longer at high
serum levels. A slower infusion rate is especially advisable for elderly
patients, and cardiac monitoring should always be performed during intra-
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venous administration. Phenytoin is probably the most frequently used
second-line agent.
Contraindications Complex cardiac arrhythmias, absence of cardiac and respiratory monitoring.
Main drug interactions Phenytoin is a potent enzyme inductor.
Main side effects Some rare but serious local reactions (eg, purple glove syndrome) are induced
by the alkaline solution, whereas phenytoin itself was associated with hypo-
tension (27%) and bradyarrhythmia (7%) in the VA study group [8]).
Fosphenytoin
Standard dosage Fosphenytoin is a water-soluble phenytoin prodrug that lacks propylene
glycol and therefore is safer as regards local tissue reactions. It is dosed in
phenytoin equivalents (PE). Although it can be infused at a faster rate than
phenytoin (150 mg PE/min), it is questionable whether effective CNS con-
centrations are reached more quickly than when phenytoin is administered
at optimal rates [22].
Contraindications Same as phenytoin.
Main drug interactions Same as phenytoin.
Main side effects Hypotension and bradyarrhythmia.
Special points Cost limits its availability in some countries.
Phenobarbital
Standard dosage Phenobarbital is loaded at 15 mg/kg (100 mg/min). It reaches the brain after
20 to 40 minutes and has a long half-life of about 100h.
Contraindications Absence of cardiac and respiratory monitoring.
Main drug interactions Phenobarbital is a potent enzyme inductor.
Main side effects Phenobarbital alsobears a consistent riskof hypotension (34% in theVA study [8]).
Special points The use of phenobarbital as a first-choice second-line agent is relatively rare.
Valproic acid
Standard dosage Valproic acid is loaded at 20 mg/kg, at high rates (up to 200 mg/min [14,23])
its elimination half-life is about 15 h. Valproic acid enters the CNS rapidly
through active transport [24]. Clinical experience in SE suggests that effective
CNS concentrations are reached within 30 minutes [23,25]. Its main advan-
tage is the lack of cardiodepressive reactions.
Contraindications Active hepatitis, pancreatitis, mitochondrial disorder.
Main drug interactions Valproic acid is an enzyme inhibitor.
Main side effects At times, follow-up of ammonium counts (especially in patients with per-
sisting slow EEGs) may be advisable, in order to detect an hyperammonemic
encephalopathy.
Special points Valproic acid is increasingly used for SE, especially in settings devoid of
cardiac and respiratory monitoring. Moreover, it represents the first choice
for absence or myoclonic SE.
Levetiracetam
Standard dosage Levetiracetam may be loaded up to 20 mg/kg [20•] its plasma half-life is
about 7 h, but its bioavailability within the blood-brain barrier is probably
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longer [26]. It is still unclear how quickly levetiracetam reaches the brain.
Monitoring of platelet counts may be advisable [19•].
Contraindications Hypersensitivity to the compound.
Main drug interactions None.
Main side effects The most frequent adverse event is mild sedation; no cardiovascular
reactions have been reported.
Special points More expensive than other second-line agents.
Lacosamide
Standard dosage Loading doses of up to 400 mg have been described [21•].
Contraindications Hypersensitivity to the compound.
Main drug interactions None known.
Main side effects Mild sedation.
Special points More expensive than other second-line agents; only anecdotal reports to date.
Third treatment line
& In generalized convulsive SE, the first treatment administered is the
most likely to be effective [9,27]. For this reason, it seems reasonable
to proceed straight to third-line treatment once the second-line
(which takes at least 20 to 30 minutes to be effective) has failed
[2,28••]. The available studies on refractory SE consist of more or
less large case series. A meta-analysis comparing barbiturates with
propofol (both acting mainly through modulation of GABAA recep-
tors) and midazolam did not show any significant difference in
short-term mortality with these three agents, although some varia-
tions were noted in efficacy (somewhat better for barbiturates) and
tolerability (somewhat worse for barbiturates); the patients treated
with barbiturates were more likely to be monitored with EEG,
however, which may explain some of the differences [29, Class IV]. A
retrospective analysis taking into account possible anesthetic com-
binations did not disclose any notable outcome difference among
the agents, whether used alone or in association [30, Class IV].
& There is also considerable uncertainty about the optimal extent of
pharmacologic EEG suppression [30] and treatment duration. An
EEG target of burst suppression with an interburst interval of about
10 s, maintained for 24 to 36 h and followed by progressive tapering
over 12 to 48 h, represents a good, practical option, but this regimen
is not yet supported by any comparative assessment.
Barbiturates
These agents include thiopental in Europe or its metabolite pentobar-
bital in North America.
Standard dosage Induction with pentobarbital is performed with boluses of 5 to 15 mg/kg the
maintenance dose is 1 to 5 mg/kg per hour. Thiopental is loaded at repetitive
boluses of 2 mg/kg and then relayed with a drip of 3 to 5 mg/kg per hour.
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These agents show a long half-life after continuous administration (pento-
barbital, 15h22h; thiopental, probably slightly longer) [31], and they have a
considerable tendency to accumulate in fat tissue, prolonging the need for
mechanical ventilation.
Contraindications Need for short-term mechanical ventilation (eg, patients with chronic obstruc-
tive pulmonary disease).
Main drug interactions Barbiturates are potent enzyme inductors.
Main side effects Hypotension and respiratory depression.
Propofol
Standard dosage The loading dose is 2 mg/kg, followed by maintenance at 2 to 10 mg/kg per
hour. Propofol has a short half-life (about 1–2 h [32]), allowing rapid titration
and withdrawal.
Contraindications Metabolic acidosis, hypertriglyceridemia, mitochondrial disorder.
Main drug interactions None.
Main side effects Sedation and respiratory depression. Especially in young children, it may
induce the “propofol infusion syndrome” (PRIS), a potentially fatal cardio-
circulatory collapse characterized by lactic acidosis, hypertriglyceridemia,
rhabdomyolysis, and green-colored urine; PRIS has been rarely described in
patients with SE [33,34•]. Concomitant benzodiazepine administration (eg,
a clonazepam or midazolam drip or repetitive short infusions of lorazepam)
could lower the propofol dose needed to obtain seizure control, possibly
reducing the risk of this complication [35]. Administration of doses over
5 mg/kg per hour for longer than 48 h should be avoided, and repetitive
checks of serum lactate could help to detect a beginning PRIS in time to
discontinue propofol.
Midazolam
Standard dosage Midazolam is loaded at 0.2 mg/kg, and then maintained at 0.1 to 0.6 mg/kg
per hour. It has a half-life of 6 to 40 h after prolonged infusion [36], with an
important habituation (tachyphylaxis) developing within 24 to 48 h [37].
Contraindications Hypersensitivity to the compound.
Main drug interactions None.
Main side effects Sedation and respiratory depression.
Special points In view of the tachyphylaxis, which requires large dosage increases after the
first day, it may be advisable to switch to one of the other options if pro-
longed treatment becomes necessary.
Other treatment approaches for persistent, refractory SE
& When SE proves resistant to the first three lines of treatment, usually
several days have elapsed since the beginning of the episode. At this
moment, it is advisable to attempt switching to another anesthetic of
the third line; doing this gives some time to titrate one further second-
line compound. It is paramount not to forget to periodically address SE
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etiology, because SE prognosis appears to be related mainly to etiology
rather than to treatment approach [30,38•,39•]. Some cases of SE
prove extremely refractory, however; this condition has been labeled
“malignant” and is encountered somewhat more often in young
patients with some form of inflammatory disease [40]. Other treatment
strategies, used relatively infrequently, havebeendescribed in anecdotal
case reports or small series; these may be employed in succession.
It is unlikely that these strategies will influence the outcome in a
decisive way, but some may be interesting in particular settings. Of
course, safety should always remain a priority for the prescribing
physician.
& Other anesthetics, such as ketamine, which acts as anNMDAantagonist
[41•, Class IV], or isoflurane [42, Class IV], an inhalation compound,
could be worth a trial. Ketamine may represent an interesting
option in view of the pathophysiology of SE; it should be com-
bined with benzodiazepines in order to minimize the risk of
neuronal toxicity.
& High-dose oral topiramate, administered through the nasogastric tube,
could be beneficial at times [43, Class IV]; this agent may modulate
AMPA receptors, in addition to sodium and calcium channels.
& Verapamil, a calcium channel blocker, inhibits the P-glycoprotein, a
multidrug transporter diminishing AED availability in the brain. Few
case reports on its use in humans with SE are available. It appears
relatively safe (under cardiac monitoring) up to dosages of 360 mg/d
[44, Class IV].
& The ketogenic diet has been prescribed for decades, mostly for
children, to control refractory seizures; its use in refractory SE as a
last resort has been described occasionally [45, Class IV]. Its effect
is exerted over several days to a few weeks.
& Immunomodulatory approaches such as steroids, intravenous
immunoglobulin, or plasma exchanges are often tried in patients
with very refractory SE [46, Class IV], at times even without evidence of
an underlying inflammatory etiology.
& Potential nonpharmacologic treatments include vagus nerve stimu-
lation initiated in the operating room [47, Class IV], mild transitory
hypothermia [48•, Class IV], and resective surgery of an isolated
epileptic focus distant from eloquent areas [49, Class IV].
How to “tune” SE treatment
It is my opinion that an important exception to the rule of treating SE quickly
and aggressively concerns SE episodes (including absence SE and several
forms of complex partial SE) in which patients are at least partly conscious.
Indeed, absence SE nearly always resolves without sequelae, and it is still
undetermined whether prolonged complex partial seizures in humans induce
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permanent structural neurologic damage [50,51]. This differs from generalized
convulsive SE, in which damage of limbic structures has been confirmed
both pathologically and radiologically. It is thus unclear whether and
when coma induction is indicated in forms of SE other than generalized
convulsive SE. In fact, this approach could predispose to several complica-
tions (eg, pneumonia, deep vein thrombosis, pulmonary embolism, neu-
ropathy, myopathy, ileus) [52].
We recently validated a clinical “Status Epilepticus Severity Score” (STESS)
[38•, Class III], allowing an estimation of prognosis before treatment is insti-
tuted (Table 1). A favorable score has an excellent negative predictive value
(0.97) for mortality: if the score is 0 to 2, the patient will likely survive the
SE episode. The score is extremely easy to use and may help to orient early
treatment strategy in unclear situations. Patients having a favorable predic-
tion may be managed less aggressively than those who have a potentially
dismal prognosis, at least at the beginning. For patients with a favorable
score, it appears advisable to try to avoid coma induction by administer-
ing nonsedating AEDs. If this approach fails to induce a notable clinical
improvement after several hours (up to 24), elective coma induction
may then be suggested.
SE episodes in patients with idiopathic generalized epilepsy (absence
or myoclonic SE) readily respond to benzodiazepines and valproate;
these patients should not be intubated. Conversely, postanoxic SE, the
expression of a severe underlying encephalopathy, is often refractory to
standard treatments, but in selected cases, after considering other prog-
nostic factors such as brainstem reflexes and somatosensory evoked
potentials, antiepileptic compounds (including anesthetics) could be pre-
scribed [53•, Class IV].
In summary, every form of SE should always be treated quickly, but the
depth of treatment should be tailored to the clinical situation. It is para-
mount to continue SE treatment, together with supportive care, in patients
with episodes refractory to treatment for several weeks or months, as long
as unmistakable evidence of irreversible neurologic damage is not found
Table 1. Status epilepticus severity score (STESS)a.
Criteria Features Score
Consciousness Alert or somnolent/confused 0
Stuporous or comatose 1
Worst seizure type Simple partial, complex partial, absence, myoclonicb 0
Generalized convulsive 1
Nonconvulsive status epilepticus in coma 2
Age G 65 y 0
≥ 65 y 2
History of previous seizures Yes 0
No or unknown 1
Totala 0–6
aA favorable score is 0 to 2
bComplicating idiopathic generalized epilepsy
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[46,54; Class IV]. Once again, one has to keep in mind that etiology, age, and
probably comorbidities are the most important predictors of outcome; the
exact role of pharmacologic treatment, other than its supportive nature,
has not yet been evaluated.
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